1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016" provides an overview of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
Clinical Trials by Region 7
Clinical Trials and Average Enrollment by Country 8
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Five Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials 28
Prominent Drugs 29
Latest Clinical Trials News on Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) 30
Jun 20, 2016: Cellectis Announces First Patient Treated in Phase 1 Trial of UCART19 in Pediatric Acute B Lymphoblastic Leukemia (B-ALL) 30
Jun 12, 2016: Pfizer Announces Final Results From Inotuzumab Ozogamicin Pivotal Phase 3 Study In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia 30
Jun 10, 2016: BLINCYTO (Blinatumomab) Improved Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia 31
Jun 10, 2016: Syros Pharmaceuticals Presents Data Demonstrating Significant Anti-Tumor Activity of its Lead Drug Candidate SY-1365 at 21st Congress of the European Hematology Association 32
Jun 10, 2016: Karyopharm Therapeutics Presents data on KPT-8602 at 2016 European Hematology Association Annual Meeting 32
Jun 04, 2016: Juno Therapeutics' Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL 33
Jun 04, 2016: Juno Therapeutics To present Data on JCAR017 at the 52nd Annual Meeting of the American Society 33
Jun 02, 2016: Kiadis Pharma announces its decision to file for marketing authorization with the European Medicines Agency (EMA) for ATIR101 in blood cancers 34
Jun 02, 2016: Seattle Children T-Cell Immunotherapy Clinical Trial for Children With Relapsed Leukemia Shows 93% Complete Remission Rate 35
May 31, 2016: Kite Pharma to Highlight Key Data from Engineered CAR T Cell Therapy Pipeline at the 2016 American Society of Clinical Oncology Annual Meeting 35
May 19, 2016: Syros Pharmaceuticals to Present on SY-1365 at 21st Congress of the European Hematology Association 36
May 18, 2016: Juno Therapeutics to Highlights New Efficacy, Safety, and Durability data for JCAR-014 at the 2016 American Society of Clinical Oncology Annual Meeting 37
May 18, 2016: Juno Therapeutics to Highlight First clinical results for JCAR017 at the 2016 American Society of Clinical Oncology Annual Meeting 37
May 18, 2016: Juno Therapeutics to Highlight JCAR-015 at the 2016 American Society of Clinical Oncology Annual Meeting 37
Apr 20, 2016: Juno Therapeutics Presents Clinical Data of JCAR018 at American Association for Cancer Research (AACR) Annual Meeting 2016 38
Apr 18, 2016: Immunomedics Announces Potent Anti-Tumor Activities with IMMU-114 in Preclinical Study in Acute and Chronic Leukemia 38
Apr 14, 2016: Juno Therapeutics Announces Updated clinical data for CD22 CAR T cell product candidate, JCAR018 at the American Association for Cancer Research Annual Meeting 39
Apr 04, 2016: Kiadis Pharma presents positive data on the primary endpoint of its single dose Phase II trial with ATIR101 40
Clinical Trial Profile Snapshots 42
Appendix 1271
Abbreviations 1271
Definitions 1271
Research Methodology 1272
Secondary Research 1272
About GlobalData 1273
Contact Us 1273
Disclaimer 1273
Source 1274

List of Tables
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Region, 2016* 7
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 14
Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Region (%), 2016* 7
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 14
Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, G7 Countries (%), 2016* 15
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) to Oncology Clinical Trials, E7 Countries (%), 2016* 18
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 1272

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

Clinical Trial Management System Market by End-user, Delivery Mode, Type, Component - Global Forecast to 2021

  • $ 5650
  • Industry report
  • August 2016
  • by MarketsandMarkets

The global clinical trial management system (CTMS) market is estimated to grow at a CAGR of 11.5% from 2016 to 2021, to reach USD 920.0 billion by 2021. The adoption of CTMS software is on the rise across ...

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

Contract Research Organizations Services Market by Type, Therapeutic Area, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The global CRO services market is estimated to grow at a CAGR of 7.4% from 2016 to 2021, to reach USD 41.86 billion by 2021 from USD 29.29 billion in 2016. Growth in this market is primarily attributed ...

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

Clinical Trial Management System (CTMS) - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • November 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Clinical Trial Management System (CTMS) market is expected to grow from $493.58 million in 2015 to reach $1118.58 million by 2022 with a CAGR of 12.4%. Huge research ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.